Stivarga

Stivarga is a prescription oral cancer medicine that contains the active ingredient regorafenib. It belongs to a class of drugs known as multikinase inhibitors, used to treat certain advanced cancers when other treatments have become ineffective. It works by slowing the growth of cancer cells and blocking the formation of new blood vessels that tumors need in order to grow. By blocking several protein kinases involved in tumor growth, Stivarga may slow cancer progression in patients with advanced disease.

Doctors usually prescribe Stivarga when a patient’s cancer has continued to progress after other treatments have already been tried. It is typically used in specialized oncology care and must be taken under the supervision of a healthcare provider experienced in cancer therapy.

Stivarga is FDA-approved to treat:

• Metastatic Colorectal Cancer (mCRC)
• Gastrointestinal Stromal Tumor (GIST)
• Hepatocellular Carcinoma (HCC)

Stivarga belongs to a class of targeted cancer therapies known as multikinase inhibitors. These drugs block multiple protein kinases that regulate cancer cell growth, tumor blood supply, and the tumor microenvironment. By inhibiting these kinases, Stivarga disrupts several biological processes required for tumor survival and spread.

Regorafenib inhibits several kinases, including VEGFR1-3, TIE2, KIT, RET, RAF-1, BRAF, PDGFR, and FGFR, which are involved in tumor growth and blood vessel formation. By blocking these signaling pathways, Stivarga reduces tumor blood supply, slows tumor growth, and may limit the spread of cancer cells. Unlike traditional chemotherapy, which affects many rapidly dividing cells, Stivarga targets specific cancer-related pathways.

• Patients with existing liver disease should use Stivarga with caution because the drug may worsen liver function.
• Individuals with a history of bleeding disorders or those taking anticoagulants should be monitored closely due to an increased risk of bleeding.
• Blood pressure should be well-controlled before starting treatment, and regular monitoring is recommended throughout therapy.
• Patients should inform their healthcare provider if they have recently had surgery or are planning to undergo surgery because the medication may affect wound healing.
• Those with a history of heart disease or cardiovascular conditions should be monitored carefully while taking Stivarga.
• Avoid breastfeeding during treatment and for 2 weeks after the final dose.
• Grapefruit and grapefruit juice should be avoided while taking Stivarga because they may increase the medication’s level in the body, increasing the risk of side effects.
• Patients should inform their healthcare provider about all prescription medications, over-the-counter drugs, vitamins, and herbal supplements they are taking to prevent potential drug interactions.

• Stivarga can cause severe and potentially life-threatening liver damage. Liver function tests should be performed before starting treatment and monitored regularly during therapy. Patients should seek emergency care if they develop symptoms such as dark urine, yellowing of the skin or eyes, persistent nausea, or severe fatigue.
• Serious and sometimes fatal bleeding may occur during treatment. Patients should report symptoms such as unusual bruising, coughing up blood, nosebleeds, or black and bloody stools.
• Stivarga may cause high blood pressure or hypertensive crisis, which requires regular monitoring during treatment.
• Stivarga may increase the risk of myocardial ischemia and heart attack, requiring medical attention if symptoms occur.
• Severe skin reactions can occur, including painful redness, blistering, and peeling of the palms of the hands or soles of the feet. Rare but serious reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis have also been reported.
• Stivarga may cause gastrointestinal perforation or fistula, which involves a tear in the stomach or intestinal wall, or an abnormal connection between organs. This condition requires immediate medical attention.
• The medication may impair wound healing. Treatment may need to be temporarily stopped before surgery and restarted only after proper healing.
• Serious infections may occur during treatment. Patients should contact their healthcare provider if they develop fever, chills, persistent cough, or other signs of infection.

Like many targeted cancer therapies, Stivarga may cause side effects. Some are mild and manageable, whereas others may require medical attention.

Stivarga should not be used in patients who:

• Are allergic to regorafenib or any component of the medication.
• Have experienced severe hypersensitivity reactions to this drug.

Before starting treatment, patients should inform their healthcare professional about all existing medical conditions.

The dosage and administration guide for Stivarga:

• Stivarga should be taken exactly as prescribed by your doctor.
• Take the tablets once a day after a low-fat meal.
• Make sure you take the medicine at the same time every day.
• Do not crush or split the Stivarga tablet. Swallow tablets whole with water.
• Follow the prescribed 28-day treatment cycle, which usually consists of 21 days of treatment followed by 7 days without medication.

If you experience a Stivarga overdose, call the Poison Control Center at 1-800-222-1222 immediately. Seek emergency medical care if symptoms such as severe fatigue, bleeding, or liver injury occur.

If you are taking Stivarga, follow the regimen as directed. If you miss a dose of Stivarga, follow a simple set of instructions:

• Take it as soon as possible.
• If it is time for your next scheduled Stivarga dose, skip the missed one.
• Do not double your Stivarga dose, as this can lead to severe consequences.

Keep the following Stivarga storage guidelines in mind to keep the medication in a proper condition:

• Store the medicine at room temperature (20°C-25°C or 68°F-77°F).
• Discard tablets 7 weeks after opening the bottle.
• Store Stivarga in the original bottle with the desiccant to protect from moisture.
• Store Stivarga in a dry place.
• Do not keep tablets in the bathroom.
• Keep out of reach of children and pets.

The following medications may interact with Stivarga. Consult your healthcare professional for the complete list of Stivarga interactions.

• Apixaban
• Alteplase
• Ashwagandha
• Anagrelide
• Binimetinib
• Bromfenac
• Betrixaban
• Cilostazol
• Clopidogrel
• Dalteperin
• Desirudin

Note: Strong CYP3A4 inhibitors (e.g., ketoconazole) or inducers (e.g., rifampin) may increase or decrease regorafenib levels.

If the medication is not available or doesn’t suit you, use the following Stivarga alternatives after consulting your doctor. The table below compares Stivarga with several commonly used alternatives in advanced colorectal cancer, gastrointestinal stromal tumors, and liver cancer.

Stivarga is generally an expensive targeted cancer medication. In the United States, the price of Stivarga can exceed, depending on dosage, pharmacy pricing, and insurance coverage. Since treatment for advanced cancers often requires long-term therapy, many patients look for ways to reduce the cost of their medication. Order Stivarga online from Canada to access additional savings and benefits.

Stivarga can be costly if you purchase it from local U.S. pharmacies, especially if you don’t have insurance coverage. At Polar Bear Meds, we help you access your prescribed medications at more affordable prices by sourcing them through fully licensed Canadian and international pharmacy partners.

You can buy Stivarga online in Canada from Polar Bear Meds and enjoy additional benefits such as:

• Competitive pricing on genuine, prescription-based Stivarga.
• Exclusive savings opportunities, including a Stivarga coupon code for additional discounts on your first order.
• Effortless shipping within 3-5 business days through our reliable courier partners like Xpress Post.

At Polar Bear Meds, your prescription is filled through licensed pharmacy partners to ensure authenticity and safety. If you are looking for a reliable and affordable way to buy Stivarga online from Canada, Polar Bear Meds offers a convenient option.

• https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=824f19c9-0546-4a8a-8d8f-c4055c04f7c7
• https://www.drugs.com/stivarga.html
• https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/regorafenib